Item 1.01 Entry into a Material Definitive Agreement.
Amended and Restated Loan and Security Agreement
On December 30, 2021, TG Therapeutics Inc. ("TG" or the "Company"), entered into
an Amended and Restated Loan and Security Agreement (the "Amendment") with
Hercules Capital, Inc., a Maryland corporation ("Hercules"), the proceeds of
which will be used for its ongoing research and development programs,
commercialization activities and for general corporate purposes. The Amendment
amended the terms of that certain Loan and Security Agreement, dated as of
February 28, 2019, by and among the Company and Hercules (the "Loan Agreement")
to, among other things, (i) increase the aggregate principal amount of the loan,
available at the Company's option, from $60.0 million to $200.0 million, (ii)
issue a first advance of $70.0 million drawn at the closing date, a portion of
which was used to refinance the current outstanding loan balance of
approximately $7.8 million, (iii) change the draw amounts and dates available in
Tranche 2 through Tranche 4 including increasing the amount available under
Tranche 2 subject to the achievement of performance milestones from $10.0
million to $20.0 million, increasing the amount available under Tranche 3
subject to the achievement of performance milestones from $10.0 million to $45.0
million, and increasing the amount under Tranche 4 subject to the approval of
Hercules' investment committee from $10.0 million to $65.0 million, (iv) extend
the maturity date of the facility from the original March 1, 2022 to January 1,
2026, (v) reset and extend the interest only period from April 1, 2021 to
February 1, 2025 and extendable to August 1, 2025 subject to the achievement of
certain performance milestones, and (vi) modify the cash interest rate to be the
greater of either (a) the "prime rate" as reported in The Wall Street Journal
plus 2.15%, and (b) 5.40%. The performance milestones are based on achievement
of certain U.S. Food and Drug Administration approvals and impact the potential
extension of the interest only period, access to future advances under the Loan
Agreement and minimum cash levels required under the Loan Agreement.
The Amendment contains financial covenants from and after October 15, 2022 that
require the Company to maintain certain levels of unrestricted cash and
additional financial covenants related to market capitalization and unrestricted
cash commencing on July 1, 2023 at any time when the term loan advances made
under the Loan Agreement are greater than $70 million.
The Amendment also contains warrant coverage of 2.95% of the total amount
funded. A warrant (the "Warrant") was issued by the Company to Hercules to
purchase 115,042 shares of common stock with an exercise price of $17.95 for the
initial amount funded at closing. The Warrant shall be exercisable for seven
years from the date of issuance. Hercules may exercise the Warrant either by (a)
cash or check or (b) through a net issuance conversion.
The foregoing description of the Amendment does not purport to be complete and
is qualified in its entirety by reference to the complete terms and conditions
of the First Amendment to be filed as an exhibit to the Company's next Form 10-K
to be filed with the U.S. Securities and Exchange Commission.
- 2 -
Item 9.01. Financial Statements and Exhibits.
Exhibit No. Description
The cover page from this Current Report on Form 8-K formatted in
Exhibit 104 Inline XBRL
- 3 -© Edgar Online, source Glimpses
TG THERAPEUTICS, INC. 
